Impact of zoledronic acid on control of metastatic spinal cord compression.
Standard
Impact of zoledronic acid on control of metastatic spinal cord compression. / Rades, D; Hakim, S G; Bajrovic, Amira; Karstens, J H; Veninga, T; Rudat, V; Schild, S E.
in: STRAHLENTHER ONKOL, Jahrgang 188, Nr. 10, 10, 2012, S. 910-916.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of zoledronic acid on control of metastatic spinal cord compression.
AU - Rades, D
AU - Hakim, S G
AU - Bajrovic, Amira
AU - Karstens, J H
AU - Veninga, T
AU - Rudat, V
AU - Schild, S E
PY - 2012
Y1 - 2012
N2 - Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).
AB - Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).
KW - Comorbidity
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Risk Factors
KW - Treatment Outcome
KW - Survival Analysis
KW - Survival Rate
KW - Prevalence
KW - Germany/epidemiology
KW - Diphosphonates/therapeutic use
KW - Bone Density Conservation Agents/administration & dosage
KW - Chemotherapy, Adjuvant/methods/mortality
KW - Imidazoles/therapeutic use
KW - Radiotherapy, Conformal/mortality
KW - Spinal Cord Compression/drug therapy/mortality/prevention & control
KW - Spinal Neoplasms/mortality/secondary/therapy
KW - Comorbidity
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Risk Factors
KW - Treatment Outcome
KW - Survival Analysis
KW - Survival Rate
KW - Prevalence
KW - Germany/epidemiology
KW - Diphosphonates/therapeutic use
KW - Bone Density Conservation Agents/administration & dosage
KW - Chemotherapy, Adjuvant/methods/mortality
KW - Imidazoles/therapeutic use
KW - Radiotherapy, Conformal/mortality
KW - Spinal Cord Compression/drug therapy/mortality/prevention & control
KW - Spinal Neoplasms/mortality/secondary/therapy
M3 - SCORING: Journal article
VL - 188
SP - 910
EP - 916
JO - STRAHLENTHER ONKOL
JF - STRAHLENTHER ONKOL
SN - 0179-7158
IS - 10
M1 - 10
ER -